Tablo Hemodialysis Platform Achieves FDA Clearance With Advanced Cybersecurity Architecture

Outset Medical has received FDA 510(k) clearance for its upgraded Tablo hemodialysis system, marking a significant milestone in medical device security. The newly approved platform represents the first hemodialysis system to fully meet the FDA's most stringent cybersecurity guidance framework issued in 2025, incorporating comprehensive protections at hardware, software, and cloud infrastructure levels. This achievement addresses a critical vulnerability in the dialysis industry, where aging systems continue to pose security risks as cyberattacks on healthcare infrastructure intensify.

Why Dialysis Systems Need Cybersecurity Upgrades

Traditional hemodialysis systems remain complex, costly, and challenging to integrate into modern hospital IT environments. Many existing dialysis devices rely on outdated software architecture, making them increasingly vulnerable under the FDA's strengthened medical device cybersecurity standards. As healthcare facilities face mounting pressure to comply with evolving security requirements, the need for enterprise-grade protection mechanisms has become urgent. Hospitals now require systems that align seamlessly with contemporary information-security protocols while safeguarding sensitive patient data and device integrity.

Tablo's Next-Generation Features and Hardware Improvements

The upgraded Tablo platform delivers comprehensive improvements beyond enhanced cybersecurity. The system incorporates operating system modernization, advanced hardware upgrades, and refined software enhancements designed to improve overall performance and reduce maintenance intervals in high-acuity clinical settings. The redesigned exterior provides hospital-grade durability suited for demanding healthcare environments. As an all-in-one hemodialysis system, Tablo integrates water purification with on-demand dialysate production, enabling flexible deployment across hospital and home-based treatment settings. This integrated approach simplifies workflow while maintaining clinical efficacy and operational reliability.

Industry Leadership and Market Deployment

More than 1,000 U.S. healthcare facilities currently utilize Tablo, with millions of treatments successfully delivered to date. The platform's widespread adoption demonstrates strong market confidence in its clinical performance and reliability. By becoming the first hemodialysis system to meet the FDA's most rigorous cybersecurity guidance, Tablo establishes a new industry standard for medical device security. This leadership position validates Outset's commitment to addressing healthcare infrastructure vulnerabilities while maintaining the therapeutic effectiveness that clinicians and patients depend on.

Timeline and Upgrade Path for Healthcare Facilities

Outset plans to commence shipments of the next-generation Tablo platform during the second quarter of 2026. Existing customers will have the opportunity to upgrade their installations to the new cybersecurity architecture, ensuring continuity of care while enhancing security posture. The phased deployment approach allows healthcare facilities to transition at their operational convenience without disrupting patient treatment schedules. This upgrade pathway reflects Outset's commitment to supporting its installed base through the transition to more secure, modern hemodialysis technology.